PharmaEngine

PharmaEngine Debt/Market Cap

The Debt to Market Capitalization Ratio of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 0.08 %. In the previous year, Debt to Market Capitalization Ratio was 0.16 % — a change of -51.77% (lower).

Debt/Market Cap

0.08 %

YoY

-51.77%

Last updated:

Debt to Market Capitalization Ratio of PharmaEngine is 2024 0.08 % . Debt to Market Capitalization Ratio of PharmaEngine was 2023 0.16 % . It decreases by -51.77% lower compared to the previous year.

The PharmaEngine Debt/Market Cap history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/Market Cap
Date
Debt/Market Cap
Jan 1, 2017
0.00 TWD
Jan 1, 2018
0.00 TWD
Jan 1, 2019
0.36 TWD
Jan 1, 2020
0.24 TWD
Jan 1, 2021
0.08 TWD
Jan 1, 2022
0.24 TWD
Jan 1, 2023
0.16 TWD
Jan 1, 2024
0.08 TWD
The PharmaEngine Debt/Market Cap history
YEARDebt/Market CapYoY
0.08 %-51.77%
0.16 %-33.73%
0.24 %+194.30%
0.08 %-65.61%
0.24 %-32.85%
0.36 %—
0.00—
0.00—
0.00—
0.00—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Debt to Market Capitalization Ratio of PharmaEngine is 0.08 % in 2024.

Debt to Market Capitalization Ratio of PharmaEngine changed from 0.16 % to 0.08 %, representing a -51.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt to Market Capitalization Ratio PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Debt/Market Cap compares total debt to the market value of equity. It provides a market-based view of financial leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt to Market Capitalization Ratio's PharmaEngine with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PharmaEngine

All Key Metrics — PharmaEngine